Trial Profile
A Phase II Study of CHOP+Rituximab (CHOP or R-CHOP) With Substitution of Liposomal Vincristine for Free Vincristine for Patients with Untreated Aggressive Non-Hodgkin's Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2014
Price :
$35
*
At a glance
- Drugs Vincristine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 25 Apr 2014 New trial record